Biocon LimitedNSE: BIOCON

Press Release Mar 27 2024

· Issued by Biocon Limited

Filed with NSE ·

On 6ix: 6ix.com/news/press-release-mar-27-2024-4

Biocon Limited has informed the Exchange regarding a press release dated March 27, 2024, titled "Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.".

View Attachment

6ix hasn’t read this filing yet.

Biocon Limited on 6ix

Earlier from Biocon

Later from Biocon

All Biocon news releases